These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 36313210)
1. Prognostic significance of sarcomatoid features in metastatic renal cell carcinoma treated with cytoreductive nephrectomy and targeted therapy. Cortese BD; Chelluri R; Xia L; Ostrowski DA; Roberson DS; Strother M; Ding JM; Schwartz L; Lee DJ; Guzzo TJ Am J Clin Exp Urol; 2022; 10(5):327-333. PubMed ID: 36313210 [TBL] [Abstract][Full Text] [Related]
2. Real-world Assessment of Clinical Outcomes in Patients with Metastatic Renal Cell Carcinoma with or Without Sarcomatoid Features Treated with First-line Systemic Therapies. Sawaya GB; Dragomir A; Wood LA; Kollmannsberger C; Basappa NS; Kapoor A; Soulières D; Finelli A; Heng DYC; Castonguay V; Canil C; Winquist E; Graham J; Bjarnason GA; Bhindi B; Lalani AK; Pouliot F; Breau RH; Saleh R; Tanguay S Eur Urol Oncol; 2024 Jun; 7(3):570-580. PubMed ID: 38097481 [TBL] [Abstract][Full Text] [Related]
3. Cytoreductive Nephrectomy for Patients with Metastatic Sarcomatoid and/or Rhabdoid Renal Cell Carcinoma Treated with Immune Checkpoint Therapy. Hahn AW; Kotecha RR; Viscuse PV; Pieretti AC; Wiele AJ; Jonasch E; Lee CH; Gao J; Zurita AJ; Shah AY; Campbell MT; Sharma P; Motzer RJ; Russo P; Wood CG; Tannir NM; Voss MH; Karam JA; Hakimi AA; Msaouel P Eur Urol Focus; 2023 Sep; 9(5):734-741. PubMed ID: 36863962 [TBL] [Abstract][Full Text] [Related]
4. Dissecting Outcomes: Should Cytoreductive Nephrectomy Be Performed for Patients With Metastatic Renal Cell Carcinoma With Sarcomatoid Dedifferentiation? Adashek JJ; Zhang Y; Skelton WP; Bilotta A; Chahoud J; Zemp L; Li J; Dhillon J; Manley B; Spiess PE Front Oncol; 2020; 10():627025. PubMed ID: 33643921 [TBL] [Abstract][Full Text] [Related]
5. Presence of sarcomatoid differentiation as a prognostic indicator for survival in surgically treated metastatic renal cell carcinoma. Gu L; Li H; Wang H; Ma X; Wang L; Chen L; Zhao W; Zhang Y; Zhang X J Cancer Res Clin Oncol; 2017 Mar; 143(3):499-508. PubMed ID: 27844145 [TBL] [Abstract][Full Text] [Related]
6. Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma. Bhindi B; Abel EJ; Albiges L; Bensalah K; Boorjian SA; Daneshmand S; Karam JA; Mason RJ; Powles T; Bex A Eur Urol; 2019 Jan; 75(1):111-128. PubMed ID: 30467042 [TBL] [Abstract][Full Text] [Related]
7. Association of preoperative serum De Ritis ratio with oncological outcomes in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma. Laukhtina E; Pradere B; D Andrea D; Rosiello G; Luzzago S; Pecoraro A; Palumbo C; Knipper S; Karakiewicz PI; Margulis V; Quhal F; Sari Motlagh R; Mostafaei H; Mori K; Kimura S; Enikeev D; Shariat SF Urol Oncol; 2020 Dec; 38(12):936.e7-936.e14. PubMed ID: 32962909 [TBL] [Abstract][Full Text] [Related]
8. Oncologic Outcomes of Cytoreductive Nephrectomy in Synchronous Metastatic Renal-Cell Carcinoma: A Single-Center Experience. Choi CI; Kang M; Sung HH; Jeon HG; Jeong BC; Jeon SS; Lee HM; Seo SIL Clin Genitourin Cancer; 2018 Dec; 16(6):e1189-e1199. PubMed ID: 30262447 [TBL] [Abstract][Full Text] [Related]
9. Benefit from cytoreductive nephrectomy and the prognostic role of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma. Day D; Kanjanapan Y; Kwan E; Yip D; Lawrentschuk N; Davis ID; Azad AA; Wong S; Rosenthal M; Gibbs P; Tran B Intern Med J; 2016 Nov; 46(11):1291-1297. PubMed ID: 27507629 [TBL] [Abstract][Full Text] [Related]
10. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. Heng DY; Wells JC; Rini BI; Beuselinck B; Lee JL; Knox JJ; Bjarnason GA; Pal SK; Kollmannsberger CK; Yuasa T; Srinivas S; Donskov F; Bamias A; Wood LA; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Kim JJ; Choueiri TK Eur Urol; 2014 Oct; 66(4):704-10. PubMed ID: 24931622 [TBL] [Abstract][Full Text] [Related]
11. The role of cytoreductive nephrectomy in metastatic renal cell carcinoma in the targeted therapy and immunological therapy era: a systematic review and meta-analysis. Chen B; Li J; Huang Y; Tang B; Jiang J; Chen Z; Li J; Wang P; Cao D; Liu L; Wei Q Int J Surg; 2023 Apr; 109(4):982-994. PubMed ID: 36974696 [TBL] [Abstract][Full Text] [Related]
12. Adverse Effect of Lymph Node Dissection in Metastatic Renal Cell Cancer Patients Treated with Cytoreductive Nephrectomy: A Contemporary Analysis of Survival. Cao D; Huang Y; Zhang C; Wu J; Yu L; Zhang H; Shi G; Ye D J Cancer; 2019; 10(19):4639-4646. PubMed ID: 31528228 [No Abstract] [Full Text] [Related]
13. Outcomes of Cytoreductive Nephrectomy for Patients with Metastatic Renal Cell Carcinoma: Real World Data from Canadian Centers. Dragomir A; Nazha S; Tanguay S; Breau RH; Bhindi B; Rendon RA; Kapoor A; Hotte SJ; Basappa N; Fairey A; So AI; Kollmannsberger C; Finelli A; Hansen A; Canil C; Heng D; Lattouf JB; Bjarnason G; Power N; Pouliot F; Wood LA Eur Urol Focus; 2022 Nov; 8(6):1703-1710. PubMed ID: 34736870 [TBL] [Abstract][Full Text] [Related]
15. A Population Study to Identify Candidates for Cytoreductive Nephrectomy in Patients with Metastatic Sarcomatoid Renal Cell Carcinoma from the Surveillance, Epidemiology, and End Results (SEER) Database. Ji B; Li D; Fu S; Zhang Z; Yang T; Wu Y; Zuo Y; Xu Z; Yu N Med Sci Monit; 2020 Jun; 26():e921297. PubMed ID: 32516796 [TBL] [Abstract][Full Text] [Related]
16. Long-term outcomes after cytoreductive nephrectomy and thrombectomy of patients with metastatic renal cell carcinoma with venous tumor thrombus: a retrospective study from a large Chinese center. Chen K; Liu Z; Li Y; Zhao X; Zhang Y; Bi H; Wang G; Liu C; Tian X; Zhang H; Ma L; Zhang S World J Surg Oncol; 2023 Jun; 21(1):170. PubMed ID: 37280590 [TBL] [Abstract][Full Text] [Related]
17. High-dose interleukin 2 in patients with metastatic renal cell carcinoma with sarcomatoid features. Achkar T; Arjunan A; Wang H; Saul M; Davar D; Appleman LJ; Friedland D; Parikh RA PLoS One; 2017; 12(12):e0190084. PubMed ID: 29261796 [TBL] [Abstract][Full Text] [Related]
18. The independent oncological role for cytoreductive nephrectomy in metastatic renal cell carcinoma: Prognostic features in the era of targeted therapies. Claeys T; Lumen N; Kumps C; Praet M; De Meerleer G; Rottey S; Ost P; Devisschere P; Villeirs G; Fonteyne V; Decaestecker K Urol Oncol; 2017 Apr; 35(4):152.e13-152.e22. PubMed ID: 28153420 [TBL] [Abstract][Full Text] [Related]
19. Prognostic effect of cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma: a comparative study using inverse probability of treatment weighting. Klatte T; Fife K; Welsh SJ; Sachdeva M; Armitage JN; 'Aho T; Riddick AC; Matakidou A; Eisen T; Stewart GD World J Urol; 2018 Mar; 36(3):417-425. PubMed ID: 29256020 [TBL] [Abstract][Full Text] [Related]
20. The impact of cytoreductive nephrectomy on survival outcomes in patients treated with tyrosine kinase inhibitors for metastatic renal cell carcinoma in a real-world cohort. Janisch F; Hillemacher T; Fuehner C; D'Andrea D; Meyer CP; Klotzbücher T; Kienapfel C; Vetterlein MW; Kimura S; Abufaraj M; Dahlem R; Shariat SF; Fisch M; Rink M Urol Oncol; 2020 Sep; 38(9):739.e9-739.e15. PubMed ID: 32576526 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]